News

Tyvaso DPI Approved by the FDA for PAH and PH-ILD

The U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI, a dry powder, inhaled formulation of treprostinil, to improve exercise ability in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso DPI is now the only dry powder inhaler approved…

Sacubitril/Valsartan Combo Found in Analysis to Improve Heart Function

Sacubitril/valsartan, a fixed-dose combination oral therapy approved for heart failure, was found to improve right heart function and lower pulmonary blood pressure, according to a new pooled analysis of multiple studies. This meta-analysis supports a new therapeutic role for sacubitril/valsartan for people with pulmonary hypertension (PH) associated with heart…

RNA Molecule FGF21 May Be Therapeutic Target

The blood levels of a signaling molecule called fibroblast growth factor 21 (FGF21) are significantly reduced in people with high-altitude pulmonary hypertension (PH) and in mice with hypoxia-induced PH, a study shows. Hypoxia refers to low oxygen conditions and chronic hypoxia is a common cause of PH. Also, treatment with…

Levels of Cytokines Differ Between Sexes With PAH, Study Suggests

The levels of blood-circulating inflammatory molecules differ between men and women with pulmonary arterial hypertension (PAH) and correlate with disease severity, a study suggests. Notably, the levels of two proteins — called IL-6 and MIP-1alpha — were predictors of poorer survival statistics. These findings suggest that patient stratification may…

Organizations Rally to Help Ukrainian Rare Disease Patients

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…